非小细胞肺癌表皮生长因子受体–酪氨酸激酶抑制剂的研究进展及其耐药后治疗策略  

Research advances of EGFR-TKI in non-small cell lung cancer and therapeutic strategy after drug resistance

作　　者：赵宏涛[1] 王喆[1] ZHAO Hong-tao;WANG Zhe(Department of Pharmacy,the Second Hospital of Tianjin Medical University,Tianjin 300211,China)

机构地区：[1]天津医科大学第二医院药学部,天津300211

出　　处：《现代药物与临床》2021年第12期2707-2712,共6页Drugs & Clinic

摘　　要：肺癌是全球死亡率最高的癌症之一,非小细胞肺癌占肺癌总人群的85%以上。约2/3的非小细胞肺癌患者在诊断时已为晚期,内科治疗是晚期非小细胞肺癌患者的主要治疗手段。近些年随着靶向治疗药物表皮生长因子受体–酪氨酸激酶抑制剂(EGFR-TKI)分子治疗的出现,非小细胞肺癌患者的治疗取得了明显的成效。但是EGFR-TKI耐药问题也接踵而至,总结了非小细胞肺癌患者EGFR-TKI治疗进展以及耐药后的治疗策略,为临床选择适合患者个体化治疗方案提供参考。Lung cancer is one of the most lethal cancers in the world. Of them, non-small cell lung cancer(NSCLC) accounts for more than 85% of the total population in China. Almost 2/3 of NSCLC patients are in advanced stage at the time of diagnosis, and medical treatment is the primary/main options for patients with advanced NSCLC. Recently, with the emergence of molecular therapy of epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI), the treatment of NSCLC has achieved remarkable progression. However, the problem of EGFR-TKI resistance is also coming. This review will summarize the treatment progress of EGFR-TKI in patients with NSCLC and the therapeutic strategies after drug resistance, so as to provide reference for clinical selection of patients with individualized treatment.

关 键 词：表皮生长因子受体–酪氨酸激酶抑制剂 非小细胞肺癌 耐药 治疗策略 

分 类 号：R979.1[医药卫生—药品]